Skip to content
10-Q

Quarterly Report

AVENUE THERAPEUTICS, INC. ATXI

0001437749-24-035309

← back to feed
Filed
Nov 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 11, 2024 1.91M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $2.6M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $1.78M
Stockholders Equity Q3 2024 · Sep 30, 2024 $2.61M
Stockholders Equity Q3 2024 · Dec 31, 2023 $1.58M
Current Liabilities Q3 2024 · Sep 30, 2024 $973K
Current Liabilities Q3 2024 · Dec 31, 2023 $1.2M
Total Liabilities Q3 2024 · Sep 30, 2024 $973K
Total Liabilities Q3 2024 · Dec 31, 2023 $1.2M
Total Assets Q3 2024 · Sep 30, 2024 $2.63M
Total Assets Q3 2024 · Dec 31, 2023 $1.85M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$7.13M
Eps Basic restated Q3 2024 · Sep 30, 2023 $4.86
Eps Basic restated Q3 2024 · Sep 30, 2023 −$115.55
Sga Expense Q3 2024 · Sep 30, 2023 $1.16M
Sga Expense Q3 2024 · Sep 30, 2023 $3.04M
Rd Expense Q3 2024 · Sep 30, 2023 $907K
Rd Expense Q3 2024 · Sep 30, 2023 $5.15M
Net Income Q3 2024 · Sep 30, 2023 $526K
Net Income Q3 2024 · Sep 30, 2023 −$11.02M
Operating Income Q3 2024 · Sep 30, 2023 −$2.07M
Operating Income Q3 2024 · Sep 30, 2023 −$12.42M